Inclusion Criteria:

• Subjects between the ages of 6 and 17, inclusive, prior to baseline dosing.
• Subjects with a diagnosis of Crohn's disease for greater than 12 weeks prior to screening, confirmed by endoscopy or radiologic evaluation.
• Subjects with a PCDAI score of > 30.
• Parent or guardian has voluntarily signed and dated an informed consent form, approved by an Institutional Review Board (IRB)/ Independent Ethics Committee (IEC).
• Parent or legal guardian must be willing to actively supervise storage and administration of study drug and to ensure that the time of each dose is accurately recorded in the subject's diary
• Adequate cardiac, renal and hepatic function as determined by principal investigator and demonstrated by Screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits.
• Subjects may have previously received infliximab, providing the subject had an initial response and then discontinued use due to a loss of response, or discontinued use due to intolerance.

Exclusion Criteria:

• History of cancer or lymphoproliferative disease other than a successfully and completely treated cutaneous squamous cell or basal cell carcinoma or carcinoma-in-situ of the cervix.
• History of listeria, histoplasmosis, chronic or active hepatitis B infection, human immunodeficiency virus (HIV), an immunodeficiency syndrome, central nervous system (CNS) demyelinating disease, or active TB (receiving treatment or not receiving treatment), severe infections such as sepsis and opportunistic infections.
• Subject with infectious colitis, ulcerative colitis or indeterminate colitis as determined by the investigator and Abbott Medical Monitor.
• Subject who has had surgical bowel resections within the past 6 months or is planning any resection at any time point while enrolled in the study.
• Subject with an ostomy or ileoanal pouch. (Subjects with a previous ileo-rectal anastomosis are not excluded).
• Subjects with any prior exposure to Tysabri (natalizumab).
• Subject who has previously used infliximab within eight weeks of Baseline.
• Subjects who have previously used infliximab and have not clinically responded at any time ("primary non-responder" are not allowed).
• Subject who received previous treatment with adalimumab or previous participation in an adalimumab clinical study.

• Subjects with a poorly controlled medical condition such as:

  • Uncontrolled diabetes mellitus
  • Moderate to severe heart failure
  • Recent cerebrovascular accidents
  • Any other condition which, in the opinion of the investigator or the sponsor, would put the subject at risk by participation in the protocol.
• Subjects currently taking both budesonide and prednisone (or equivalent).